FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Richard Silver

Research Profile

Disorders

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Srdan Verstovsek; Elliott F Winton; Murat O Arcasoy; John V Catalano; Michael Deininger; John F Dipersio; Susan Erickson-Viitanen; Jason Gotlib; Vikas Gupta; Jimmie H Harvey; Elizabeth Hexner; Richard S Levy; Roger M Lyons; Ruben A Mesa; Carole Miller; Ronald Paquette; Azra Raza; Victor Sandor; Richard T Silver; William Sun; Moshe Talpaz; Kris Vaddi; Hagop M Kantarjian
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
Richard T Silver; Jean-Jacques Kiladjian; Hans Carl Hasselbalch
Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.
Emil Kuriakose; Katherine Vandris; Y Lynn Wang; William Chow; Paul Christos; Nicholas C P Cross; Amy V Jones; Richard T Silver
Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Richard Silver (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Srdan Verstovsek; Elliott F Winton; Murat O Arcasoy; John V Catalano; Michael Deininger; John F Dipersio; Susan Erickson-Viitanen; Jason Gotlib; Vikas Gupta; Jimmie H Harvey; Elizabeth Hexner; Richard S Levy; Roger M Lyons; Ruben A Mesa; Carole Miller; Ronald Paquette; Azra Raza; Victor Sandor; Richard T Silver; William Sun; Moshe Talpaz; Kris Vaddi; Hagop M Kantarjian
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
British journal of haematology 2013;161(4):508-16.
2013: Richard T Silver; Jean-Jacques Kiladjian; Hans Carl Hasselbalch
Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.
Expert review of hematology 2013;6(1):49-58.
2012: Emil Kuriakose; Katherine Vandris; Y Lynn Wang; William Chow; Paul Christos; Nicholas C P Cross; Amy V Jones; Richard T Silver
Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.
Haematologica 2012;97(4):538-42.
2012: Srdan Verstovsek; Elliott F Winton; Murat O Arcasoy; John V Catalano; Michael Deininger; John F DiPersio; Susan Erickson-Viitanen; Jason Gotlib; Vikas Gupta; Jimmie H Harvey; Elizabeth Hexner; Iphigenia L Koumenis; Richard S Levy; Roger M Lyons; Ruben A Mesa; Carole B Miller; Ronald Paquette; Azra Raza; Victor Sandor; Richard T Silver; William Sun; Moshe Talpaz; Kris Vaddi; Hagop M Kantarjian
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
The New England journal of medicine 2012;366(9):799-807.
2011: Richard T Silver; Katherine Vandris; Joshua J Goldman
Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report.
Blood 2011;117(24):6669-72.
2011: Richard T Silver; Katherine Vandris; Y Lynn Wang; Fernando Adriano; Amy V Jones; Paul J Christos; Nicholas C P Cross
JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy.
Leukemia research 2011;35(2):177-82.
2011: Richard T Silver
Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time?
The oncologist 2011;16(5):554-8.
2009: Richard T Silver
The blast phase of chronic myeloid leukaemia.
Best practice & research. Clinical haematology 2009;22(3):387-94.
2007: Ruben A Mesa; Srdan Verstovsek; Francisco Cervantes; Giovanni Barosi; John T Reilly; Brigitte Dupriez; Ross Levine; Marie-Caroline Le Bousse-Kerdiles; Martha Wadleigh; Peter J Campbell; Richard T Silver; Alessandro M Vannucchi; H Joachim Deeg; Heinz Gisslinger; Deborah Thomas; Olatoyosi Odenike; Lawrence Solberg; Jason Gotlib; Elizabeth Hexner; Stephen D Nimer; Andrew Lamb; Attilio Orazi; James W Vardiman; Juergen Thiele; Ayalew Tefferi
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).
Leukemia research 2007;31(6):737-40.
2007: Richard T Silver; john bennett; J M Goldman; Jerry L Spivak; Ayalew Tefferi
The third International Congress on Myeloproliferative and Myelodysplastic Syndromes.
Leukemia research 2007;31(1):11-7.
2006: Ayalew Tefferi; Giovanni Barosi; Ruben A Mesa; Francisco Cervantes; H Joachim Deeg; John T Reilly; Srdan Verstovsek; Brigitte Dupriez; Richard T Silver; Olatoyosi Odenike; Jorge Cortes; Martha Wadleigh; Lawrence Solberg; John K Camoriano; Heinz Gisslinger; Pierre Noel; Juergen Thiele; James W Vardiman; Ronald Hoffman; Nicholas C P Cross; D Gary Gilliland; Andrew Lamb
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
Blood 2006;108(5):1497-503.
2006: Jerry L Spivak; Alison R Moliterno; Richard T Silver
Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2.
The New England journal of medicine 2006;355(7):737; author reply 738.
2006: Tsiporah Shore; John Harpel; Michael W Schuster; Gail J Roboz; John P Leonard; Morton Coleman; Eric J Feldman; Richard T Silver
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2006;12(8):868-75.
2004: Richard T Silver; john bennett; Michael W N Deininger; Eric Feldman; Shahin Rafii; R L Silverstein; Lawrence Solberg; Jerry L Spivak
The second international congress on myeloproliferative and myelodysplastic syndromes.
Leukemia research 2004;28(9):979-85.
2004: Sherif S Farag; Amy S Ruppert; Krzysztof Mrózek; Andrew J Carroll; Mark J Pettenati; Michelle M Le Beau; Bercedis L Peterson; Bayard L Powell; Howard Ozer; Richard T Silver; Richard A Larson; Clara D Bloomfield
Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study.
International journal of oncology 2004;25(1):143-51.
2004: Jerry L Spivak; Richard T Silver
Imatinib mesylate in polycythemia vera.
Blood 2004;103(8):3241; author reply 3241-2.
2003: Eric Feldman; Vesna Najfeld; Michael Schuster; Gail J Roboz; Amy Chadburn; Richard T Silver
The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate.
Experimental hematology 2003;31(8):702-7.
2003: Richard T Silver; Bercedis L Peterson; Ted P Szatrowski; Bayard L Powell; Wendy Stock; Andrew J Carroll; Clara D Bloomfield; Charles Alan Schiffer; Richard A Larson
Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
Leukemia & lymphoma 2003;44(1):39-48.
2002: Gail J Roboz; Mary Ann Knovich; R L Bayer; Michael W Schuster; Karen Seiter; Bayard L Powell; R D Woodruff; Richard T Silver; A E Frankel; Eric J Feldman
Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia.
Leukemia & lymphoma 2002;43(10):1951-5.
2001: A Sirulink; Richard T Silver; Vesna Najfeld
Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571.
Leukemia 2001;15(11):1795-7.
2000: Martee Hensley; B Peterson; Richard T Silver; Richard A Larson; Charles Alan Schiffer; Ted P Szatrowski
Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(6):1301-8.
1997: Wendy Stock; Carol A Westbrook; B Peterson; D C Arthur; Ted P Szatrowski; Richard T Silver; Dorie A Sher; Ding Wu; Michelle M Le Beau; Charles Alan Schiffer; Clara D Bloomfield
Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):26-36.